News

Results of Phase III ReMoxTB Clinical Trial Published

Moxifloxacin

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a more rapid decrease in mycobacterial load, moxifloxacin containing regimens did not shorten TB treatment to 4 months as predicted.

For more information on the REMoxTB trial results, see here for the TB Alliance press release.

Related Links

Publication in New England Journal of Medicine

TB Alliance Press Release

TB Alliance Graphic

PanACEA: A new approach to tuberculosis research

Moxifloxacin struggles against current TB Drugs: REMox Trials

Additional Links

REMox TB Consortium

TB Alliance

More News
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...